ADMA Biologics Inc. shareholders approved the company's planned acquisition of certain assets from Biotest Pharmaceuticals Corp.

The assets include facilities and certain Biotest employees in Boca Raton, Fla., a U.S. Food and Drug Administration-licensed product portfolio including Nabi-HB and Bivigam, and contract manufacturing and services agreement for a third party's licensed hyperimmune globulin product.

The acquisition is expected to close in June.

Biotest Pharmaceuticals is a wholly owned subsidiary of Biotest AG.